arrow
M

Martin J. van den Bent

erasmus mc cancer institute
H指数:128
被引数:10.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The role for surgery in IDH-mutant grade 4 astrocytomas: Interactive effects of resection, patient characteristics, and outcome—Report of the RANO resect group

IDH突变型4级星形细胞瘤中手术的作用:切除、患者特征和预后的交互影响——RANO切除组的报告

2026-08-310
PRE
ESTRO, ESNR, and EORTC consensus-based definition for MRI abnormalities after radiotherapy for intracranial central nervous system tumors

ESTRO、ESNR和EORTC基于共识的颅内中枢神经系统肿瘤放疗后MRI异常定义

2026-08-200
PRE
CTNI-09. VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2/3 ASTROCYTOMA: STUDY PROTOCOL FOR THE PLACEBO-CONTROLLED, TRIPLE-BLIND, RANDOMIZED PHASE III STUDY EORTC-2427 (VIGOR)

VORASIDENIB CTNI-09作为IDH突变2/3级星形细胞瘤一线放化疗后的维持治疗: 安慰剂对照,三盲,随机III期研究EORTC-2427 (VIGOR) 的研究方案

2025-11-110
OA
Volumetric (3D) compared with traditional bidirectional (2D) assessment in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial

与接受vorasidenib或安慰剂治疗的Grade 2,异柠檬酸脱氢酶1/2突变(mIDH1/2)胶质瘤患者中,体素(3D)评估相较于传统双向(2D)评估在INDIGO III期试验中的比较

2025-11-010
OAAI
Health-Related Quality of Life in Molecular Glioma Subtypes: A Pooled Analysis from 16 Randomized Trials

分子胶质瘤亚型的健康相关生活质量:一项来自16项随机试验的合并分析

2025-11-010
OAAI
PROGNOSTIC AND PREDICTIVE MARKERS FOR OUTCOME IN PATIENTS WITH IDHMT TUMORS TREATED IN THE EORTC CATNON TRIAL ON ADJUVANT AND/OR CONCURRENT TEMOZOLOMIDE IN ANAPLASTIC ASTROCYTOMA

IDHMT肿瘤患者在接受EORTC CATNON试验中辅助和/或同步替莫唑胺治疗的间变性星形细胞瘤中的预后和预测性生物标志物

2025-11-010
OAAI
A comprehensive framework for intraoperative mapping and monitoring, and perioperative neurological, linguistic, and outcome assessment in glioma resection: Consensus recommendations from the PIONEER Consortium and RANO resect group

胶质瘤切除术中的综合框架:包括术中定位与监测、围手术期神经功能、语言功能及预后评估,PIONEER Consortium 和 RANO resect group 共识建议

2025-11-010
OAAI
Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial

体积肿瘤生长率(TGR)建模预测了在INDIGO三期试验中,接受vorasidenib或安慰剂治疗的Grade 2、异柠檬酸脱氢酶1/2突变(mIDH1/2)胶质瘤患者的临床结局。

2025-11-010
OAAI
A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicenter, retrospective study with external validation by the RANO resect group

IDH突变型2级胶质瘤切除范围的预后分类系统:一项由RANO resect group进行外部验证的国际、多中心、回顾性研究

2025-11-010
PRE